- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06027242
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
September 6, 2023 updated by: National Taiwan University Clinical Trial Center, National Taiwan University Hospital
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism.
The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy.
The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This will be a double-blind, randomized, and placebo-controlled study.
At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group.
Each group will have at least 40 patients.
The CT scan will be evaluated before surgery and on postoperative day (POD) 90.
Moreover, the patient will wear the smart watch to record daily walking steps.
Laboratory data will be check before gastrectomy and on POD 90.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Jin-Ming Wu, MD
- Phone Number: 886-223123456
- Email: wujm0531@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- adult gastric cancer receiving gastrectomy
Exclusion Criteria:
- Hepatic insufficiency
- Renal insufficiency
- can not tolerate oral or enteral feeding 7 days after gastrectomy
- can not receive computed tomograph
- can not waer the wearable devices
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Without oral glutamine supplementation
15 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
|
Maltodextrin
|
Active Comparator: With oral glutamine supplementation
10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
|
Maltodextrin
10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of area of psoas muscle
Time Frame: 84 days after gastrectomy
|
area od psoas muscle on the CT scan
|
84 days after gastrectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Walking steps
Time Frame: 28,56, and 84 days after gastrectomy
|
the average daily walking steps recorded by the wearable devices
|
28,56, and 84 days after gastrectomy
|
body weight
Time Frame: 84 days after gastrectomy
|
body weight
|
84 days after gastrectomy
|
Change of serum albumin value
Time Frame: 84 days after gastrectomy
|
84 days after gastrectomy
|
|
Change in white blood cells counts
Time Frame: 84 days after gastrectomy
|
84 days after gastrectomy
|
|
Change in lymphocyte cells counts
Time Frame: 84 days after gastrectomy
|
84 days after gastrectomy
|
|
Change of serum pre-albumin value
Time Frame: 84 days after gastrectomy
|
84 days after gastrectomy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jin-Ming Wu, MD, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 21, 2023
Primary Completion (Estimated)
August 30, 2026
Study Completion (Estimated)
August 30, 2026
Study Registration Dates
First Submitted
August 17, 2023
First Submitted That Met QC Criteria
September 5, 2023
First Posted (Actual)
September 7, 2023
Study Record Updates
Last Update Posted (Actual)
September 8, 2023
Last Update Submitted That Met QC Criteria
September 6, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202207099RINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Maltodextrin
-
Northwestern UniversityUniversity of Illinois at ChicagoActive, not recruitingParkinson Disease | Dietary Modification | Intestinal Bacteria Flora DisturbanceUnited States
-
University of BathUniversity of BirminghamCompleted
-
NestléCompleted
-
University of FoggiaCasa Sollievo della Sofferenza IRCCSActive, not recruitingCesarean Section ComplicationsItaly
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIV | Breast Feeding | Infant MorbiditySouth Africa
-
Biofortis, Merieux NutriSciencesLonza Inc.CompletedGut MicrobiotaUnited States
-
SyralBiofortis Mérieux NutriSciences; CreaBio Rhone-AlpesCompletedHealthy | Functional ConstipationFrance
-
Nanjing PLA General HospitalCompletedIrritable Bowel Syndrome
-
NestléCompletedSeasonal Allergic RhinitisSwitzerland
-
NestléCompletedCeliac Disease | Non-celiac Gluten SensitivityNetherlands